A glycocalyx-mimetic supplement significantly reduced urinary peptide biomarkers of heart failure risk in type 2 diabetics over 12 weeks, while a fasting-mimicking diet and placebo had no effect.
HF2 score −0.58 (p<0.001)Glycocalyx supplement significantly reduced the urinary peptidomic heart failure risk classifier over 12 weeks in type 2 diabetics
What the researchers found
Glycocalyx-mimetic supplementation significantly reduced heart failure risk scores (HF2) by a mean of -0.58 (95% CI: -0.83 to -0.33, adjusted p<0.001) as measured by urinary peptidomic classifiers. The supplement altered 17 urinary peptides, primarily decreasing collagen-derived fragments, suggesting improved extracellular matrix turnover. Coronary artery disease (CAD160) and chronic kidney disease (CKD273) risk scores were unchanged. Neither the fasting-mimicking diet nor placebo produced meaningful changes in any classifier.
Why it matters
Type 2 diabetes dramatically increases cardiovascular risk. This study shows a dietary supplement can measurably improve a validated biomarker of heart failure risk — using cutting-edge peptidomic technology to detect changes at the molecular level. The glycocalyx (the protective lining of blood vessels) is damaged in diabetes, and this is one of the first interventional studies showing it can be therapeutically targeted with a supplement.
How the study worked
This was a follow-up analysis of a prior placebo-controlled trial. Forty-four South-Asian Surinamese adults with type 2 diabetes were randomly allocated to 12 weeks of daily glycocalyx-mimetic capsules (n=18), placebo (n=14), or a 5-day fasting-mimicking diet repeated every 4 weeks (n=12). Urine samples at baseline and week 12 were analyzed using capillary electrophoresis-mass spectrometry. Three pre-validated peptide classifiers scored risk for heart failure, coronary artery disease, and chronic kidney disease.
Who was studied
South-Asian Surinamese adults with type 2 diabetes mellitus
What this study cannot tell us
Small sample size of only 44 participants across three groups. The study population was limited to South-Asian Surinamese adults, which may limit generalizability. Only urinary peptide biomarkers were measured — no hard clinical endpoints like actual heart failure events. CAD and CKD risk scores did not change, limiting the scope of cardiovascular benefit. The 12-week duration may be too short to detect all effects.
How to read the evidence
This is a small randomized controlled trial (n=44) using validated biomarker endpoints rather than clinical events. The peptidomic classifiers are pre-validated but the sample size limits statistical power and generalizability.
When this study was published
Published in 2025, this is very recent research at the frontier of glycocalyx therapeutics and peptidomic monitoring.
The bigger picture
The glycocalyx — a fragile sugar-protein layer coating blood vessel walls — is increasingly recognized as critical for vascular health and is damaged early in diabetes. This study represents a new therapeutic strategy: rather than treating downstream cardiovascular complications, repair the glycocalyx itself. The use of urinary peptidomics as a monitoring tool is also innovative, offering a non-invasive way to track vascular health changes at the molecular level.
Questions still open
- Would glycocalyx-mimetic supplementation also improve CAD and CKD risk scores with longer treatment or larger doses?
- Do the peptidomic improvements translate to actual reductions in heart failure events over years of follow-up?
- Would glycocalyx supplementation benefit non-diabetic populations at cardiovascular risk?
Common questions
What is the glycocalyx and why does it matter for diabetes?
What are urinary peptidomic classifiers?
Read the original research
Dietary glycocalyx mimetic reduces vascular risk in Type 2 diabetes: evidence from urinary peptidomic classifiers in a South-Asian Surinamese Cohort.
Diabetes research and clinical practice, 229, 112931
Citation
Biglari, Sajjad; Yuan, Lushun; Mischak, Harald; Siwy, Justyna; Latosinska, Agnieszka; Banasik, Miroslaw; van den Berg, Bernard M. (2025). Dietary glycocalyx mimetic reduces vascular risk in Type 2 diabetes: evidence from urinary peptidomic classifiers in a South-Asian Surinamese Cohort.. Diabetes research and clinical practice, 229, 112931. https://doi.org/10.1016/j.diabres.2025.112931